HAG
VRTX icon

HighPoint Advisor Group’s Vertex Pharmaceuticals VRTX Stock Holding History

HighPoint Advisor Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$528K Buy
1,063
+108
+11% +$47.9K 0.02% 454
2026
Q1 		$426K Sell
955
-5,134
-84% -$2.39M 0.02% 452
2025
Q4 		$2.76M Buy
6,089
+1,585
+35% +$683K 0.06% 261
2025
Q3 		$1.76M Buy
4,504
+467
+12% +$195K 0.08% 178
2025
Q2 		$1.8M Buy
4,037
+26
+0.6% +$12K 0.1% 170
2025
Q1 		$2.02M Buy
4,011
+406
+11% +$189K 0.12% 140
2024
Q4 		$1.64M Buy
3,605
+120
+3% +$55.6K 0.09% 179
2024
Q3 		$1.64M Sell
3,485
-943
-21% -$453K 0.1% 166
2024
Q2 		$2.23M Buy
4,428
+506
+13% +$220K 0.13% 130
2024
Q1 		$1.69M Buy
3,922
+334
+9% +$141K 0.12% 145
2023
Q4 		$1.49M Buy
+3,588
New +$1.33M 0.11% 153
2022
Q2 		$511K Buy
+1,754
New +$469K 0.06% 282
2021
Q3 		– Sell
-1,100
Closed -$222K – 598
2021
Q2 		$222K Buy
+1,100
New +$230K 0.02% 475
2020
Q3 		– Sell
-2,508
Closed -$718K – 406
2020
Q2 		$718K Buy
2,508
+103
+4% +$27.9K 0.15% 123
2020
Q1 		$649K Sell
2,405
-790
-25% -$181K 0.15% 115
2019
Q4 		$747K Buy
+3,195
New +$647K 0.15% 120
2019
Q2 		– Sell
-5,041
Closed -$858K – 502
2019
Q1 		$858K Sell
5,041
-56
-1% -$10.3K 0.21% 93
2018
Q4 		$952K Buy
5,097
+160
+3% +$27.7K 0.25% 94
2018
Q3 		$876K Hold
4,937
– – 0.24% 101
2018
Q2 		$864K Buy
+4,937
New +$765K 0.23% 113

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HighPoint Advisor Group's VRTX Position: Q2 2026 in Review

HighPoint Advisor Group increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, buying an estimated $47.9K and bringing the position to 1,063 shares worth $528K. The position accounts for 0.02% of the portfolio, ranked #454.

HighPoint Advisor Group first reported a position in VRTX in Q2 2018 and has held it in 20 quarters since. The position peaked at $2.76M in Q4 2025. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • HighPoint Advisor Group held 1,063 shares of Vertex Pharmaceuticals worth $528K as of Q2 2026.
  • HighPoint Advisor Group bought 108 Vertex Pharmaceuticals shares in Q2 2026, an estimated $47.9K.
  • Vertex Pharmaceuticals made up 0.02% of HighPoint Advisor Group's portfolio in Q2 2026, its #454 holding.
  • HighPoint Advisor Group first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 20 quarters since.
  • HighPoint Advisor Group's Vertex Pharmaceuticals position peaked at $2.76M in Q4 2025.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on HighPoint Advisor Group's 13F filing for Q2 2026, filed 5 Aug 2026.